Orforglipron

Study · 2026

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison

Aims This study aimed to indirectly compare the effects of oral semaglutide 25 mg versus orforglipron 36 mg on body weight loss, other cardiometabolic biomarkers, and tolerability in adults with overweight (body mass index [BMI] ≥ 27 kg/m 2 and at least one obesity-related complication) or obesity (BMI ≥ 30 kg/m 2 ), w…

review · 2026

Orforglipron and the emergence of oral GLP-1 therapy for obesity: efficacy, safety, and clinical positioning

Introduction Obesity is a chronic, relapsing disease associated with substantial cardiometabolic morbidity and reduced quality of life.

Study · 2026

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial

Incretins have improved the management of obesity and its related complications, but maintaining these health benefits requires ongoing administration, which can be challenging.

Study · 2026

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight

Aims To evaluate the bioequivalence of orally administered orforglipron tablets and capsules in participants with obesity or overweight who were otherwise healthy. Materials and methods This phase 1, multicenter, open-label, multiple-dose, dose-escalation study was conducted in 429 healthy adults.

Study · 2026

Orforglipron (Foundayo) - a second oral GLP-1 receptor agonist for weight loss

Study · 2026

In T2D inadequately controlled with metformin, orforglipron reduced HbA<sub>1c</sub> more than oral semaglutide at 52 wk

Clinical impact ratings GIM/FP/GP: [Formula: see text] Endocrinology: [Formula: see text].